Elemental and optical imaging evaluation of zwitterionic gold nanoclusters in glioblastoma mouse models

Nanoscale ◽  
2018 ◽  
Vol 10 (39) ◽  
pp. 18657-18664 ◽  
Author(s):  
Xavier Le Guével ◽  
Maxime Henry ◽  
Vincent Motto-Ros ◽  
Elena Longo ◽  
Maria I. Montañez ◽  
...  

We report the in vivo biodistribution of luminescent gold nanoclusters (NCs) stabilized by bidentate zwitterionic molecules in subcutaneous and orthotopic glioblastoma mice models.

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6020
Author(s):  
Francesca Maria Orlandella ◽  
Luigi Auletta ◽  
Adelaide Greco ◽  
Antonella Zannetti ◽  
Giuliana Salvatore

Background: We have conducted a systematic review focusing on the advancements in preclinical molecular imaging to study the delivery and therapeutic efficacy of miRNAs in mouse models of breast cancer. Methods: A systematic review of English articles published in peer-reviewed journals using PubMed, EMBASE, BIOSIS™ and Scopus was performed. Search terms included breast cancer, mouse, mice, microRNA(s) and miRNA(s). Results: From a total of 2073 records, our final data extraction was from 114 manuscripts. The most frequently used murine genetic background was Balb/C (46.7%). The most frequently used model was the IV metastatic model (46.8%), which was obtained via intravenous injection (68.9%) in the tail vein. Bioluminescence was the most used frequently used tool (64%), and was used as a surrogate for tumor growth for efficacy treatment or for the evaluation of tumorigenicity in miRNA-transfected cells (29.9%); for tracking, evaluation of engraftment and for response to therapy in metastatic models (50.6%). Conclusions: This review provides a systematic and focused analysis of all the information available and related to the imaging protocols with which to test miRNA therapy in an in vivo mice model of breast cancer, and has the purpose of providing an important tool to suggest the best preclinical imaging protocol based on available evidence.


2020 ◽  
Vol 11 ◽  
pp. 533-546 ◽  
Author(s):  
Nonappa

Luminescent nanomaterials have emerged as attractive candidates for sensing, catalysis and bioimaging applications in recent years. For practical use in bioimaging, nanomaterials with high photoluminescence, quantum yield, photostability and large Stokes shifts are needed. While offering high photoluminescence and quantum yield, semiconductor quantum dots suffer from toxicity and are susceptible to oxidation. In this context, atomically precise gold nanoclusters protected by thiol monolayers have emerged as a new class of luminescent nanomaterials. Low toxicity, bioavailability, photostability as well as tunable size, composition, and optoelectronic properties make them suitable for bioimaging and biosensing applications. In this review, an overview of the sensing of pathogens, and of in vitro and in vivo bioimaging using luminescent gold nanoclusters along with the limitations with selected examples are discussed.


The Analyst ◽  
2020 ◽  
Vol 145 (2) ◽  
pp. 348-363 ◽  
Author(s):  
Huili Li ◽  
Hongle Li ◽  
Ajun Wan

This review highlights the pharmacokinetic features and tumor imaging preponderance of renal clearable AuNCs for in vivo tumor imaging.


2016 ◽  
Vol 135 ◽  
pp. 64-79 ◽  
Author(s):  
Andrea Cantelli ◽  
Giulia Battistelli ◽  
Gloria Guidetti ◽  
Jeannette Manzi ◽  
Matteo Di Giosia ◽  
...  

2021 ◽  
Author(s):  
Francesca Maria Orlandella ◽  
Luigi Auletta ◽  
Adelaide Greco ◽  
Antonella Zannetti ◽  
Giuliana Salvatore

Abstract Background: miRNAs have been defined as a tumor suppressor or oncogene (oncomiR) in several human cancers. We have conducted a systematic review highlighting and specifically focusing in the advancements in preclinical molecular imaging to study in vivo the delivery and the therapeutic efficacy of miRNAs in mouse models of breast cancer.Methods: A systematic review of English articles published in peer-reviewed journals using PubMed® (including MEDLINE®), EMBASE, BIOSIS™, Scopus was performed. Search terms included breast cancer, mouse, mice, microRNA(s) and miRNA(s). The search was focused on the last five years (2015-2021). All studies using miRNA in breast cancer models which included a preclinical imaging evaluation, both in vivo or ex vivo were analyzed. Result: From a total of 2,073 records, 1,221 papers were assessed for full text eligibility, but excluding all those in which there was no use of mouse models of breast cancer, there was not in vivo imaging or ex vivo on whole organs, and without a clear link to a miRNA, our final data extraction was made on a total of 114 manuscripts. The murine genetic background most used in miRNA studies have been resulted to be the Balb/C (46,7%). Regarding cell lines, MDA-MB-231 parental and derived cells were used in most experiments (62,5%). The most used model was the i.v. metastatic model (46,8%), which was obtained via intravenous injection (68,9%) in the tail vein. The modulation of miRNA was obtained mainly by stable transfection with specific lentiviral plasmid or DNA constructs in luciferase- labelled BC cells (54,4%). Bioluminescence resulted the most used tool (64%) and was used as a surrogate of tumor growth for efficacy treatment or for the evaluation of tumorigenicity in miRNA transfected cells (29,9%); for tracking, evaluation of engraftment and for response to therapy in metastatic models (50,6%).Conclusion: this review provides a systematic and focused analysis of all the information currently available and related to the imaging protocols to test miRNA therapy in in vivo mice model of BC and has the purpose to provide an important tool to suggest the best pre-clinical imaging protocol on currently available evidences.


Sign in / Sign up

Export Citation Format

Share Document